Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
Marvel Biosciences Announces Testing MB-204 on Autism by French University
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
Marvel Biosciences Invited to Test MB-204 on Autism by French University
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.